Proteomics Research of Osteosarcoma (PROS001)

Zhejiang University

Status: Unknown

Conditions: Osteosarcoma; Proteomics

Treatments: Drug: Chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT03932058

PR-OS-001

Details and patient eligibility

About

Retrospectively collected 400 cases of clinical data and pathological paraffin specimens of osteosarcoma, chondrosarcoma (control) and endogenous chondroma (control) in our hospital from 2008 to 2014, combined with high-pressure cycle-satellite scanning mass spectrometry (PCT-SWATH) Molecular typing of osteosarcoma and prediction of targeted therapy, the establishment of a new molecular classification based on proteomics for osteosarcoma to predict the chemotherapy response and recurrence risk of osteosarcoma. Clinical osteosarcoma patients include as many types as possible: pre-chemotherapy, post-chemotherapy, recurrence, and metastasis. The study did not involve vulnerable groups, and it was taken as a postoperative wax specimen for patients, which had no health, life and other effects on patients. Study application exemption from informed consent.

Enrollment: 400 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• all osteosarcoma patients in our hospital
• received Methotrexate+Doxorubicin+Cisplatin protocol chemotherapy

Exclusion criteria

• non-chemotherapy patients
• bio-specimen not completed

Trial design

400 participants in 3 patient groups

osteosarcoma

Treatment:

Drug: Chemotherapy

chondrosarcoma

enchondroma